Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 22, 2015 01:00 ET | Source: Addex Therapeutics

Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 22 July 2015 -...
June 12, 2015 01:00 ET | Source: Addex Therapeutics

Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 12 June 2015 -...
June 03, 2015 01:00 ET | Source: Addex Therapeutics

Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland 3 June 2015 -...
May 29, 2015 01:00 ET | Source: Addex Therapeutics

Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} 5th Biennial Workshop on Dystonia...
May 27, 2015 09:50 ET | Source: Addex Therapeutics

Addex Annual General Meeting Scheduled for 11 June 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland 27 May 2015 -...
May 07, 2015 01:00 ET | Source: Addex Therapeutics

Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} ...
April 30, 2015 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics Reports 2014 Financial Results

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} 2014 Financial Highlights Increased...
March 09, 2015 02:00 ET | Source: Addex Therapeutics

Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 9 March 2015 -...
February 23, 2015 01:00 ET | Source: Addex Therapeutics

Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 23 February 2015...
February 19, 2015 01:00 ET | Source: Addex Therapeutics

Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 19 February 2015...